EIDOS THERAPEUTICS, INC. Shares of Common Stock, par value $0.001 per share Underwriting AgreementEidos Therapeutics, Inc. • June 8th, 2018 • Pharmaceutical preparations • New York
Eidos Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.
OPEN MARKET SALE AGREEMENTSMEidos Therapeutics, Inc. • August 2nd, 2019 • Pharmaceutical preparations • New York
EIDOS THERAPEUTICS, INC. DIRECTOR INDEMNIFICATION AGREEMENTIndemnification Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 201[ ] by and between Eidos Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
OFFICE LEASE BY AND BETWEEN a California limited partnership AS LANDLORD AND ElDOS THERAPEUTICS, INC., a Delaware corporation, AS TENANT PREMISES: San Francisco, CaliforniaOffice Lease • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
THIS OFFICE LEASE (this “Lease”) is made as of the 14th day of November, 2017, by and between 101 Montgomery Street Co., a California limited partnership (“Landlord”), and Eidos Therapeutics, Inc., a Delaware corporation (“Tenant”).
EIDOS THERAPEUTICS, INC. INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 23rd, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of April, 2016, by and among Eidos Therapeutics, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 5.9 hereof.
VOTING AGREEMENTVoting Agreement • October 7th, 2020 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT, dated as of October 5, 2020 (this “Agreement”), is between Eidos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the parties listed on Schedule A hereto (each, a “Stockholder” and, collectively, the “Stockholders”).
INTERCOMPANY SERVICES AGREEMENTIntercompany Services Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
This INTERCOMPANY SERVICES AGREEMENT (this “Agreement”), dated May 1, 2017 and effective as of May 1, 2017 (the “Effective Date”), is made and entered into by and between BridgeBio Services Inc., a Delaware corporation (the “Provider”), and Eidos Therapeutics, Inc., a Delaware corporation (the “Recipient”). The Provider and the Recipient may be referred to collectively herein as the “Parties” and each, a “Party.”
EIDOS THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 29th day of March, 2018, by and among Eidos Therapeutics, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 5.9 hereof.
NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY CONSULTANTS UNDER THE EIDOS THERAPEUTICS, INC.Non-Qualified Stock Option Agreement • April 15th, 2019 • Eidos Therapeutics, Inc. • Pharmaceutical preparations
Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Eidos Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
LICENSE AGREEMENT between Alexion Pharma International Operations Unlimited Company and Eidos Therapeutics, Inc. DATED September 9, 2019License Agreement • October 31st, 2019 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (this “Agreement”) is made as of September 9, 2019 (the “Effective Date”), by and between Eidos Therapeutics, Inc., a Delaware corporation (“Eidos”), having a place of business at 101 Montgomery Street, Suite 2550, San Francisco, California 94104, USA, and Alexion Pharma International Operations Unlimited Company, an Irish unlimited company (“Alexion”), having a place of business at College Business & Technology Park, Blanchardstown, Dublin 15, Ireland. Eidos and Alexion are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
QB3@953 Sublease Agreement (the “Agreement”)953 Sublease Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations
QB3 Incubator Partners, LP (“Landlord”) and Eidos Therapeutics, Inc., a State of Delaware C-Corporation (“Tenant”) agree as follows:
ContractPurchase Agreement • March 23rd, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 18th, 2019 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 13, 2019 (the “Effective Date”), among (a) SILICON VALLEY BANK, a California corporation, in its capacity as administrative agent and collateral agent (“Agent”), (b) SILICON VALLEY BANK, a California corporation, as a lender (“SVB”), (c) HERCULES CAPITAL, INC., a Maryland corporation (“Hercules”), as a lender (SVB and Hercules and each of the other “Lenders” from time to time a party hereto are referred to herein collectively as the “Lenders” and each individually as a “Lender”), and (d) EIDOS THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Agent and the Lenders shall lend to Borrower, and Borrower shall repay Agent and the Lenders. The parties agree as follows:
S09-398 : CKC EXCLUSIVE (EQUITY) AGREEMENT CONFIDENTIALExclusive (Equity) Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
This Exclusive (Equity) Agreement (this “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eidos Therapeutics, Inc. (“Eidos”), a corporation having a principal place of business at 12354 Skyline Boulevard, Woodside, CA 94062, is effective on the 10th day of April, 2016 (“Effective Date”).
FIRST LOAN MODIFICATION AGREEMENTFirst Loan Modification Agreement • January 26th, 2021 • Eidos Therapeutics, Inc. • Pharmaceutical preparations
This First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of January 25, 2021, by and among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as administrative agent and collateral agent (“Agent”), (b) SILICON VALLEY BANK, a California corporation, as a lender, (c) HERCULES CAPITAL, INC., a Maryland corporation (“Hercules”), as a lender (SVB and Hercules and each of the other “Lenders” from time to time a party hereto are referred to herein collectively as the “Lenders” and each individually as a “Lender”), and (d) EIDOS THERAPEUTICS, INC., a Delaware corporation (“Borrower”).
LEASE AMENDMENT NUMBER ONELease Amendment Number One • April 15th, 2019 • Eidos Therapeutics, Inc. • Pharmaceutical preparations
This LEASE AMENDMENT NUMBER ONE (the “Amendment”) is made on this ____27th________ day of March, 2019, by and between 101 Montgomery Street Co., a California limited partnership, (“Landlord”) and Eidos Therapeutics, Inc., a Delaware corporation (“Tenant”).
BONUS AGREEMENTBonus Agreement • May 25th, 2018 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • California
This bonus agreement (this “Agreement”) is entered into as of April 26, 2018 (the “Effective Date”) by and between Eidos Therapeutics, Inc. (the “Company”) and Neil Kumar (the “Executive”). All capitalized terms set forth below and not defined shall have the respective meanings set forth in Section 4 of this Agreement.
